Treatment of Human Brucellosis with Rifampin plus Minocycline

Scarlata, Francesco; Giordano, Sharon H.; Antinori, Spinello; Colomba, Claudia; Titone, Lucina

doi:10.1179/joc.2003.15.3.248

Cited by 24 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Little is known about the potential toxicity of a higher dose of RMP, as most data are derived from non-comparative cohort studies. [10][11][12][13][14][15] A systematic review of 14 randomised trials using higher doses of RMP showed that hepatotoxicity was rarely observed. 16 However, the authors state that 'additional data on safety will be needed'.…”

mentioning

confidence: 99%

A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis

Jindani

Borgulya

Patino

et al. 2016

int j tuberc lung dis

View full text Add to dashboard Cite

mentioning

confidence: 99%

A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis

Jindani

Borgulya

Patino

et al. 2016

int j tuberc lung dis

View full text Add to dashboard Cite

“…Our results represent the first from a study of the molecular characterization of rpoB mutations in resistant Brucella strains and provide an additional proof of the association of specific rpoB mutations with the development of the Rif r phenotype in prokaryotes. In addition, because of the relationship between Rif r and the attenuation of virulence in Brucella spp., studies of virulence in these mutants may provide useful information about the genetic basis of pathogenesis in Brucella.Rifampin is one of the most potent and broad-spectrum antibiotics against bacterial pathogens and is an important component of effective multidrug therapies for the treatment of brucellosis in humans (2,5,26). Previously reported data have indicated that the addition of rifampin to media tends to turn Brucella abortus cultures rough and that organisms with rifampin resistance (Rif r ) are less virulent than rifampin-susceptible (Rif s ) strains (17, 23).…”

mentioning

confidence: 99%

“…Rifampin is one of the most potent and broad-spectrum antibiotics against bacterial pathogens and is an important component of effective multidrug therapies for the treatment of brucellosis in humans (2,5,26). Previously reported data have indicated that the addition of rifampin to media tends to turn Brucella abortus cultures rough and that organisms with rifampin resistance (Rif r ) are less virulent than rifampin-susceptible (Rif s ) strains (17, 23).…”

mentioning

confidence: 99%

Genetic Bases of the Rifampin Resistance Phenotype inBrucellaspp

et al. 2004

View full text Add to dashboard Cite

Rifampin is one of the most potent and broad-spectrum antibiotics against bacterial pathogens. Its bactericidal activity is due to its ability to bind to the ␤ subunit of the DNA-dependent RNA polymerase encoded by the rpoB gene. Mutations of the rpoB gene have been characterized in rifampin-resistant (Rif r ) strains of Escherichia coli and Mycobacterium tuberculosis. The genetic bases of Rif r in Brucella spp. are still unknown. In the present study, the nucleotide sequences of the rpoB gene of the Rif r vaccine strain Brucella abortus RB51 and of 20 Rif r clones derived in our laboratory from two Brucella melitensis isolates were determined. These sequences were then compared to those of the respective rifampin-susceptible (Rif s ) parental strains and to the published B. melitensis strain 16M. All Rif r strains carried one or more missense mutations mapping in two regions of the rpoB gene. These two "hot" regions were investigated in eight additional Rif r Brucella laboratory mutants and in 20 reference Rif s Brucella strains. rpoB mutations were found in all Rif r mutants. In contrast, no missense mutations were found in any analyzed Rif s strains. Our results represent the first from a study of the molecular characterization of rpoB mutations in resistant Brucella strains and provide an additional proof of the association of specific rpoB mutations with the development of the Rif r phenotype in prokaryotes. In addition, because of the relationship between Rif r and the attenuation of virulence in Brucella spp., studies of virulence in these mutants may provide useful information about the genetic basis of pathogenesis in Brucella.Rifampin is one of the most potent and broad-spectrum antibiotics against bacterial pathogens and is an important component of effective multidrug therapies for the treatment of brucellosis in humans (2,5,26). Previously reported data have indicated that the addition of rifampin to media tends to turn Brucella abortus cultures rough and that organisms with rifampin resistance (Rif r ) are less virulent than rifampin-susceptible (Rif s ) strains (17, 23). Rifampin was therefore utilized to obtain the stable, rough, and attenuated B. abortus strain RB51, currently used in the United States as the official vaccine for brucellosis eradication in cattle. The roughness and attenuation are two important characteristics for the vaccine strain RB51, which is able to induce an adequate, protective cell-mediated response against infection with virulent Brucella strains without interfering with standard serological tests for brucellosis diagnosis (7,15,16,18,19,20,22,27). Strain RB51 was derived by repeated passaging of the smooth and virulent B. abortus strain 2308 on media supplemented with rifampin (23). Its high level of Rif r constitutes a useful biochemical marker for its identification. This characteristic was used to develop a selective medium to assist in the recovery of the vaccine strain RB51 from experimental and field samples for its isolation (10).The genetic bases for Rif r in ...

show abstract

“…We found a 3-week course of oral minocycline (2.5 mg/kg) in combination with intravenous rifampin (10 mg/kg), both twice daily, to be very effective in treating brucellosis at any age (4).…”

mentioning

confidence: 98%